



Regulatory Pathways in the US and EU

PMC Virtual Tutorial 12 September 2023

Agenda

1. Fundamentals: Regulation of clinical lab tests in the US

- a) Key agencies / stakeholders and regulations
- b) PMA, 510k, de novo definitions, including CDx
- c) IVD and LDT pathways

2. US market entry considerations

3. Fundamentals: Regulation of clinical lab tests in the EU

- a) IVDR overview including agencies / stakeholders and regulations including timelines
- b) In-house tests
- c) Companion diagnostics

4. Testing in clinical trials

- a) IVDR compliance requirements for tests in clinical trials
- b) Compliance requirements and implications: Testing EU trial samples in US

5. Summary and Q&A





Fundamentals: Regulation of clinical lab tests in the US



Regulatory Body	Role	Primary authority/standard
FDA (Food & Drug Administration)	Develops & implements federal regulations and guidelines for IVD tests	Federal Food Drug & Cosmetic Act (FD&C Act); IVD tests must be safe and effective for the claimed intended use
CMS (Centers for Medicare & Medicaid Services)	(1) Regulates labs that perform testing on human specimens and report patient-specific results for use in clinical diagnosis, prevention, treatment, or assessment	 (1) Clinical Laboratory Improvement Amendments (CLIA) - Ensure accurate and reliable clinical test results; excludes research use
CMS.gov	(2) Establishes clinical laboratory tests coverage/payment policies for the Medicare and Medicaid programs	(2) Tests must be reasonable and necessary for clinical care





Fundamentals: Key U.S. regulatory authorities & stakeholders



Regulatory Body	Role	Primary authority/standard	
State Agencies (SAs)	Oversee lab licensing, process CLIA applications & maintain records	In addition to federal requirements, federal regulations, some state health departments have their own requirements	
FTC (Federal Trade Commission) Investigates deceptive advertising practices and enforces consumer protection laws FEDERAL TRADE COMMISSION PROTECTING AMERICA'S CONSUMERS		<i>Federal Trade Commission Act</i> (FTC Act) – advertising/scientific claims about clinical tests must be truthful and not misleading	
3rd Party Accreditors (CAP; Joint Commission) Offer accreditation and conduct peer inspections for clinical laboratories. COLLEGE of AMERICAN PATHOLOGISTS COLLEGE of AMERICAN		Under CLIA, CMS may deem 3 rd parties for inspections in lieu of CMS.	





	Laboratory Developed Test ("LDT")	In Vitro Diagnostic Device ("IVD")
Setting	 Designed, developed and furnished by a <u>single</u> high complexity CLIA certified laboratory Generally, does NOT require FDA clearance/approval 	 "Manufactured" and distributed as "kit" to multiple CLIA labs or furnished as a "single-site IVD" Generally, requires FDA clearance/approval
Intended Use/ Indications for Use	 Indications are not restricted by FDA (must be <i>truthful</i> and not misleading as per FTC) Must establish test performance characteristics under CLIA (limited validation data) 	 Indications are limited to FDA cleared/approved labeling Each indication requires comprehensive validation data to assure reasonable "safety & effectiveness"
Quality Systems	 CLIA certification required; CAP accreditation is typical Design control & ISO certification NOT required NOT subject to FDA inspections 	 Product /components must be developed under QSR (FDA quality systems regulations including ISO 13485) Subject to FDA inspections
FDA Submission	 Generally, LDTs are under FDA "enforcement discretion" (see FDA ProCode QQS) However, <u>NOT "exempt" from FDA oversight</u> - as a subset/type of IVD medical device, FDA submission could be required to continue offering the test LDTs with FDA clearance/approval are called "single-site IVD" medical devices 	 Must submit comprehensive "valid scientific evidence" FDA submission must include evidence of: Design control from sample collection to result Software design control and validation Performance data (analytical and clinical validity) Clinical utility/outcomes and cost data NOT required or reviewed by FDA





Fundamentals: FDA pathways in U.S. are risk-based per Intended Use



Regulatory Pathway	Risk Assessment*	Requirements	
PMA ("premarket application")	High (Class 3)	 Intended use already classified as high risk/Class 3, or an IVD with no legally marketed predicate New devices with novel intended use and/or technology are, automatically by default, classified as Class III, but may be "down" classified to Class 2; requires valid scientific evidence 	
De Novo ("request for classification")	Moderate (Class 2)	 New device with novel intended use and/or technology with risks lower than Class III (moderate risk) <i>Risk assessment</i>: Could special controls mitigate risks? Yes = de novo /moderate risk classification (class 2) 	
510(k) ("pre-market notification")	Moderate (Class 2)	 "Class 2" IVD with a legally marketed predicate Must be "substantially equivalent" to its predicate (same Intended Use; limited differences in technological characteristics) 	
Registration & Listing ("510(k) Exempt")	Low (Class 1)	Most Class 1 (and some Class 2) IVD devices do NOT require FDA submission. Must meet general controls (including quality systems regulations) unless Intended Use is specifically exempted	
IDE (Investigational Device Exemption)	Significant Risk(SR) vs Non-Significant Risk (NSR)	Clinical Trial Assays (CTAs) and clinical studies determined to be a "significant risk" must have an IDE in addition to IRB oversight. For "non-significant risk" studies the IRB acts in place of the IDE.	

*FDA's primary risk consideration is the risk to human health from false results!

Fundamentals: Regulatory requirements for Clinical Trial Assays (CTA) in the U.S.



Pathway	Investigational Use Only (IUO) – Non-Significant Risk (NSR)	Investigational Use Only (IUO) – Significant Risk (SR)	
Intended use settings	CLIA certified lab	CLIA certified lab	
Patient-specific results report	Report labeled as "For Investigational Use Only"	Report labeled as "For Investigational Use Only"	
Regulatory requirements	 IRB oversight May be single site assay or kit distributed to multiple labs Abbreviated IDE requirements (IRB oversight - no FDA submission) 	 IRB oversight IDE submission to FDA ✓ Design control procedures ✓ Abbr. Manufacturing ✓ Software development ✓ AV data (accuracy, precision & LOD studies) ✓ Prior clinical investigations ✓ Clinical study protocol 	
Typical Pharma requirements for CTA (compared to LDT use only)	 CTAs are used in clinical studies and typically tailored to pharma trial <u>Diagnostic partner should be prepared to meet additional standards</u>: ✓ Specific turn around times (TAT) ✓ More validation data to pharma's requirements ✓ QMS showing complete system level information (e.g., design control) for pharma audit IDE requirements for LDTs remain unclear for FDA's new CDx Oncology Pilot Program 		



US market entry considerations

U.S. Market Entry: Product comparisons for commercial/clinical tests



LDT	IVD - Single Site	IVD - Distributed	CDx	DTC access
Clinical test designed, developed & performed <u>in a single clinical lab</u>	LDT that has been FDA cleared/approved for use in a single clinical lab	IVD "kit" that has been FDA cleared/approved for distribution to more than one clinical lab	IVD (distributed kit or single-site) that provides information "necessary for the safe & effective use" of corresponding drug/ biologic	IVD (distributed kit or single- site) or LDT sold directly to patients and/or consumers
 Must be CLIA/CAP certified FDA submission is generally <u>voluntary</u> Could be subject to (potential) new FDA regulations 	 Must be CLIA/CAP certified Unless exempt, must be FDA cleared/approved Design controls required FDA QSR compliant QMS required 	 Unless exempt, must be FDA cleared/ approved Design controls required FDA QSR compliant QMS required 	 "CDx" determination is drug focused - made per FDA-Center for Drug Research and Evaluation (CDER) LDTs indicated for such CDx –high FDA enforcement risk 	 FDA submission required for certain LDT indications (e.g., COVID-19 Dx; PGx) Typically includes "at home" sample collection FDA requires additional human factors studies and labeling for IVDs
Invitae CRC panel	Myriad BRCAnalysis CDx	PGDx Elio Tissue Complete	Thermo Fisher Oncomine Dx	23andMe PGS PGx



Myriad genetics

PGDx





U.S. Market Pathways: 2 options for drug response/therapy management indications



"COMPANION DIAGNOSTIC" (CDx)

Device type: Next generation sequencing oncology panel, somatic or germline detection system

FDA Product Code ("ProCode"): PQP Risk Classification: High (Class 3 device) Requirement: PMA submission

Identification/definition:

- For professional use only (Rx)
- For CDx use (*i.e.*, test result is determined by FDA to provide information that is *"essential for safe and effective use of a corresponding"* therapeutic product)

Example:

Results of the **Myriad BRACAnalysis CDx** test "...are used as an aid in identifying ovarian cancer patients with deleterious or suspected deleterious germline BRCA variants eligible for treatment with LynparzaTM (olaparib)." [PMA Number: P140020]





"PHARMACOGENETIC TEST "(PGx)

Device type: direct-to-consumer access pharmacogenomic assessment system

FDA Product Code ("ProCode"): QDJ Risk Classification: Moderate (Class 2 device) Requirement: 510(k) submission (see 21 CFR 862.3364)

Identification/definition:

- For use OTC/DTC*
- Intended use: ".....for the purpose of assessing the presence of genetic variants that impact the metabolism, exposure, response, risk of adverse events, dosing, or mechanisms of prescription or over-the-counter medications."
- Limitation: "...must not include an indication for use in supporting or sustaining human life, being of substantial importance in preventing impairment of human health, or presenting a potential, unreasonable risk of illness or injury." (e.g., not for CDx use)

Example:

Results of the **23anMe Personal Genome Service** (PGS) test Pharmacogen describe[s] if a person has variants associated with metabolism of some the does not describe if a person will or will not respond to a particular therape not describe the association between detected variants and any specific the appearer. Lee Novo Number: DEN180028]

*Over-the-counter/direct-to-consumer access IVDs do not require prescription/professional authorization).



U.S. Market Entry – Additional Regulatory Considerations in the U.S.

Managing Assay Modifications

- Predetermined Change Control Plan ("PCCP") <u>New</u> FDA regulatory tool for managing ongoing changes to software/assays <u>without</u> a new FDA submission
- FDA guidance available for managing reagent/instrument changes, software updates
- $\,\circ\,\,$ Evolving policies may enable single-site IVDs avoid serial number controls for instrumentation

Potential regulatory changes

- \circ New federal legislation VALID, MCED, CLIA expansion unlikely to be enacted
- $\circ~$ New FDA regulations modifications to medical device regulations
 - Explicit FDA regulation of LDTs (proposed and under review at OMB/White House https://www.reginfo.gov/public/do/eoDetails?rrid=325012)
 - ISO 13485 harmonization with FDA quality systems regulations (soon to be published as "final" regulations)*

*The extent to which additional FDA QSR requirements remain following harmonization will be determined by the final rule.





U.S. Market Entry: Use Case Scenario # 1 - LDT

- I am a laboratory located in Europe
- I have a cancer diagnostic assay
- My assay has been self-certified under IVDD and is marketed in the EU countries (under transition period)

I am looking to enter US market as an LDT. What are the regulatory considerations?

The following key requirements should be considered for entering the US market as an LDT (others may apply):

- Establishing CLIA /CAP laboratory
- > Transferring the technology and implementing the assay in the Lab
- > Validating the test meeting CLIA requirements
- > Complying with state specific regulatory requirements
- > Investing in implementation of FDA compliant QMS (for data traceability and Pharma collaboration opportunities)





U.S. Market Entry: Use Case Scenario # 2 - Distributed Kit IVD

- I am a laboratory located in Europe
- I have a distributed kit for a cancer diagnostic assay
- I have a CE mark to offer the test in 5 European countries
- I have ISO 13485 certified manufacturing facility



I am looking to distribute my assay in the United states (in all states). What are the regulatory considerations?

The following key requirements should be considered for entering the US market as a distribute kit IVD (others may apply):

- > Achieving FDA premarket authorization (unless the device meets exemption requirements)
 - Request for an authorization most likely would need to include clinical validation data on US population
- Completing an FDA inspection of the European manufacturing facility
- > Completing establishment registration and device listing
- Identifying a qualified US agent





U.S. Market Entry: Use Case Scenario # 3 - CTA

- I am a laboratory located in Europe
- I have a distributed kit for a cancer diagnostic assay
- I have a CE mark and offer the test in 5 European countries
- I have ISO 13485 certified manufacturing facility

I am looking to partner with pharma for selecting patients for their clinical trials in the US. What are the regulatory considerations?

The following key requirements should be considered for entering the US market as a CTA (others may apply):

- Obtaining IRB approvals for each clinical site
- > Determining level of risk for use of the device in every clinical trial
- > Obtaining an FDA IDE (if the use of considered as significant risk)
- > Preparing for QMS audit from a pharma partner







U.S. Market Entry Key regulatory considerations for successful test launch in U.S.




	If launching as an LDT / Partner with Pharma for CTA	If entering the U.S. market with an IVD
1 Regulatory strategy	Mitigate FDA enforcement risk!	Clarify desired intended use/indication (desired "claims") based on gap assessment; consider Breakthrough Designation Request
2 Regulatory compliance	 FDA and CLIA regulations "co-exist" ✓ CLIA certification is absolutely required if are patient-specific results are reported to anyone ✓ IRB is needed for both significant risk and non-significant risk clinical studies 	 Identify indications for least burdensome FDA submission, e.g.: ✓ Comprehensive predicate search ✓ Risk assessment focused on risk to the patient/human health from a FALSE RESULT vs benefit to patient/human health ✓ Develop a Predetermined Chance Control Plan (PCCP)
FDA submission	LDTs as CTAs require risk determination for submission requirements	Confirm adequate data per FDA (analytical and clinical performance data, not clinical utility & cost data)



Fundamentals: Regulation of clinical lab tests in the EU

In Vitro Diagnostic Medical Device Definition





IVD Medical Device





Definition of Companion Diagnostic (CDx)

'Companion diagnostic' (CDx) is defined in Article 2.7 IVDR as a device which is essential for the safe and effective use of a corresponding medicinal product to:


- a) identify, before and/or during treatment, patients who are most likely to benefit from the corresponding medicinal product; or
- b) identify, before and/or during treatment, patients likely to be at increased risk of serious adverse reactions as a result of treatment with the corresponding medicinal product.

General CDx examples (non-exhaustive):

- A device intended to identify a marker (receptor, transporter, other protein-based biomarker or its variant) specifically targeted by the corresponding medicinal product.
- Devices intended to detect antibodies against a specific medicinal product during the course of treatment.
- Devices intended to identify patients who are expected to benefit from treatment with a specific medicinal product, based on the absence of a marker.

MDCG 2020-16 rev.2 Guidance on Classification Rules for in vitro Diagnostic Medical Devices under Regulation 2017/746

Annex II: Flowchart to help determine whether an IVD is a CDx







In-Vitro Diagnostic Directive

Sets out general rules that are transferred to national law by each member state.



In-Vitro Diagnostic Regulation 2017/746 EC (IVDR)

May 26, 2022

Directly applicable in all European Member states. Leaves no room for local interpretation.




'Conformity Assessment' means the process demonstrating whether the requirements of the Regulation relating to a device have been fulfilled





CE Marking: Stakeholders EU









IVD Classification and impact on the Conformity Assessment





IVDR and New Transition Timelines (Regulation 2022/112)







In House - IVDR – Art 5.5 Restriction of application

- Devices can only be defined as in-house devices if:
 - Manufacture and use is limited to health institutions established in the EU
 - The devices are not transferred to another legal entity;
 - Manufacture and use of the devices occur under appropriate quality management systems, the compliant with standard EN ISO 15189 or [...];
 - Documented justification that the target patient group's specific needs cannot be met, or cannot be met at the appropriate level of performance by an equivalent device available on the market;
 - The health institution provides information upon request on the use of such devices to its competent authority, which shall include a justification of their manufacturing, modification and use;




Timeline for the application of the different provisions of IVDR Article 5(5)

181

26

May

2022








Testing in clinical trials





- ✓ CE-marked
- ✓ In-house, Article 5.5
- ✓ Device for performance study





Testing EU trial samples in US

There is no general answer but several considerations:

- ✓ General Data Protection Regulation (GDPR)
 - o Information provided in the clinical trial application?
 - o Information given in the Informed consent?
 - Appropriate safeguards related to data subject rights in place (no approved legal framework EU/US, GDPR compliance)?

✓ Compliance IVDR

- $\circ\;$ Test impacts the medical management decisions? (if yes, need to comply to IVDR)
- $\circ~$ What is the current regulatory status of the device in EU?
- Applicability of Article 6
- ✓ National law(s) related to management of data protection and/or genetic data









Study Submission – EU Regulatory Requirements








IVDR, Art. 57: General requirements regarding performance studies







IVDR, Art. 58: Additional requirements for certain performance studies





Summary and Q&A

Thank you.